Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.
复制标题
DOI：
10.1038/s41467-022-35358-3
复制
发表时间：
2022-12-22
影响因子：
16.6
通讯作者：
Horwood, Nicole J.
中科院分区：
文献类型：
--
作者：
Leng, Houfu;Zhang, Hanlin;Li, Linsen;Zhang, Shuhao;Wang, Yanping;Chavda, Selina J.;Galas-Filipowicz, Daria;Lou, Hantao;Ersek, Adel;Morris, Emma V.;Sezgin, Erdinc;Lee, Yi-Hsuan;Li, Yunsen;Lechuga-Vieco, Ana Victoria;Tian, Mei;Mi, Jian-Qing;Yong, Kwee;Zhong, Qing;Edwards, Claire M.;Simon, Anna Katharina;Horwood, Nicole J.
Patients with multiple myeloma, an incurable malignancy of plasma cells, frequently develop osteolytic bone lesions that severely impact quality of life and clinical outcomes. Eliglustat, a U.S. Food and Drug Administration-approved glucosylceramide synthase inhibitor, reduced osteoclast-driven bone loss in preclinical in vivo models of myeloma. In combination with zoledronic acid, a bisphosphonate that treats myeloma bone disease, eliglustat provided further protection from bone loss. Autophagic degradation of TRAF3, a key step for osteoclast differentiation, was inhibited by eliglustat as evidenced by TRAF3 lysosomal and cytoplasmic accumulation. Eliglustat blocked autophagy by altering glycosphingolipid composition whilst restoration of missing glycosphingolipids rescued autophagy markers and TRAF3 degradation thus restoring osteoclastogenesis in bone marrow cells from myeloma patients. This work delineates both the mechanism by which glucosylceramide synthase inhibition prevents autophagic degradation of TRAF3 to reduce osteoclastogenesis as well as highlighting the clinical translational potential of eliglustat for the treatment of myeloma bone disease. Here, the authors show that the glycosylceramide synthesis inhibitor and FDA approved drug Eliglustat inhibits autophagic degradation of TRAF3 which is a key step for osteoclast differentiation and thereby improves myeloma bone lesions.
登录
查看更多内容
影响因子：
64.8
作者：
Diao, Jiajie;Liu, Rong;Rong, Yueguang;Zhao, Minglei;Zhang, Jing;Lai, Ying;Zhou, Qiangjun;Wilz, Livia M.;Li, Jianxu;Vivona, Sandro;Pfuetzner, Richard A.;Brunger, Axel T.;Zhong, Qing
通讯作者：
Zhong, Qing
DOI：
10.1007/s10495-015-1092-6
发表时间：
2015-05
期刊：
Apoptosis : an international journal on programmed cell death
影响因子：
--
作者：
Garcia-Ruiz C;Morales A;Fernández-Checa JC
通讯作者：
Fernández-Checa JC
影响因子：
4.9
作者：
Abian, Olga;Alfonso, Pilar;Sancho, Javier
通讯作者：
Sancho, Javier
影响因子：
5.6
作者：
Chicote J;Yuste VJ;Boix J;Ribas J
通讯作者：
Ribas J
影响因子：
4.8
作者：
Armstrong, AP;Tometsko, ME;Dougall, WC
通讯作者：
Dougall, WC